modernretina3d
FDA clears investigational new drug (IND) application for HG202 by HuidaGene Therapeutics
This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...
modernretina4d
Study examines the use of AI–based detection of diabetic retinopathy in the US
A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...
modernretina6d
e-therapeutics shares update on AMD candidate ETX-407
The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD). e-therapeutics plc, shared business updates across a variety of areas.
modernretina6d
Patient selection for GA therapy
Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy. Clinicians’ attitudes toward geography atrophy (GA) and treatment have been changing in the short ...
modernretina6d
GA therapies coming down the pike
Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference. There is a great need for more ...